The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Bone Health Observational Study
Official Title: A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).
Study ID: NCT00632905
Brief Summary: Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced Bone Loss(CTIBL) in their patients. The gold standard for evaluating BMD is dual energy x-ray absorptiometry (DEXA). The proposed study will provide some of the first prospective data on the rates of Skeletal Related Events (SREs) in prostate cancer patients undergoing ADT and help develop official guidelines on the use of DEXA screening for prostate cancer patients.
Detailed Description: A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss (CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a specific subset of patients who would most benefit from the treatment. By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to identify that specific sub-set of patients who would most benefit from the treatment. Using a prospective, observational study design, we propose monitoring how physicians manage CTIBL in their patients.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Dr. John A. Warner, Burnaby, British Columbia, Canada
Southern Interior Medical Research Corporation, Kelowna, British Columbia, Canada
Nanaimo Urology Associates, Nanaimo, British Columbia, Canada
Central Island Research Centre, Port Alberni, British Columbia, Canada
Andreou Research, Surrey, British Columbia, Canada
Bruce W. Palmer Urology Inc., Kentville, Nova Scotia, Canada
Dr. Jonathan L. Giddens, Brampton, Ontario, Canada
Brantford Urology Research Medical Arts Bldg., Brantford, Ontario, Canada
G. Kenneth Jansz Medicine Professional Corporation, Burlington, Ontario, Canada
Dr. Richard Sowery, Burlington, Ontario, Canada
Guelph Urology Associates, Guelph, Ontario, Canada
Dr. Alvaro Morales, Kingston, Ontario, Canada
GU Trials Markham, Markham, Ontario, Canada
Mor Urology Inc, Newmarket, Ontario, Canada
Medical & Dental Bldg, North Bay, Ontario, Canada
Stanley Flax Medicine Professional Corporation, North York, Ontario, Canada
York-Finch Med Centre, North York, Ontario, Canada
The Fe/Male Health Centres, Oakville, Ontario, Canada
Orillia Urology Associates, Orillia, Ontario, Canada
Urotec, Oshawa, Ontario, Canada
Mahoney Medicine Professional Corporation, Ottawa, Ontario, Canada
2150935 Ontario Inc, Owen Sound, Ontario, Canada
Kawartha Urology Associates, Peterborough, Ontario, Canada
The Medical Centre, Peterborough, Ontario, Canada
Dr. Allan Abramovitch, Scarborough, Ontario, Canada
Dr. Peter Roney, Smiths Falls, Ontario, Canada
Northern Urology Centre, Sudbury, Ontario, Canada
West Arthur Place, Thunder Bay, Ontario, Canada
Dr. Edward Woods, Toronto, Ontario, Canada
The Male Health Centre, Toronto, Ontario, Canada
Dr. Roger Buckley, Willowdale, Ontario, Canada
ABHM Associates, Windsor, Ontario, Canada
Dr. Louis-Rene Barrette, Chicoutimi, Quebec, Canada
Recherches Cliniques Theradev, Granby, Quebec, Canada
Polyclinique Med Concorde, Laval, Quebec, Canada
Ultra-Med Inc., Point Claire, Quebec, Canada
Clinique d'Urologie du Saguenay, Saguenay, Quebec, Canada
Centre de Récherche en Urologie de Lanaudiére, St. Charles-Baromee, Quebec, Canada
Westmount Med Bldg, Westmount, Quebec, Canada
Medical Arts Bldg, Saskatoon, Saskatchewan, Canada
Name: Richard W Casey, M.D.
Affiliation: CMX Research
Role: PRINCIPAL_INVESTIGATOR